Mobile

A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderate t...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013235-38

A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety/tolerability of 52 weeks of treatment with QVA149 (110μg indacaterol/50μg glycopyrrolate) once a day on adverse event reporting rate in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD)

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens